Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ELOA antisense RNA 1 (ELOA-AS1) is a human gene that encodes a long non-coding RNA transcribed from the ELOA locus on chromosome 1. It is classified as an antisense RNA, meaning it is transcribed from the strand opposite to the ELOA (elongin A) gene. Antisense RNAs like ELOA-AS1 can potentially regulate the expression of adjacent or overlapping protein-coding genes through various mechanisms but there is currently no direct evidence for a defined biological function, disease role, or drug targeting of ELOA-AS1[1][4][6]. ELOA-AS1 is not considered a canonical drug target, and no drugs or biomarkers are currently associated with it[4][6]. Expression data indicate presence in tissues such as the adrenal gland and cortex, but biological significance is unclear[5]. If structured database information for this lncRNA becomes available in the future, associations with gene regulation, disease roles, or biomarker utility could be added. For now, it remains a well-defined gene entity without established therapeutic relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ELOA antisense RNA 1 (ELOA-AS1).